KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ClearPoint Neuro (CLPT) EBT (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed EBT for 13 consecutive years, with -$7.8 million as the latest value for Q4 2025.

  • Quarterly EBT fell 43.63% to -$7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.5 million through Dec 2025, down 34.83% year-over-year, with the annual reading at -$25.5 million for FY2025, 34.83% down from the prior year.
  • EBT hit -$7.8 million in Q4 2025 for ClearPoint Neuro, down from -$5.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$2.5 million in Q1 2021 to a low of -$7.8 million in Q4 2025.
  • Historically, EBT has averaged -$4.9 million across 5 years, with a median of -$4.6 million in 2022.
  • Biggest five-year swings in EBT: tumbled 174.41% in 2021 and later surged 38.4% in 2024.
  • Year by year, EBT stood at -$4.1 million in 2021, then dropped by 7.79% to -$4.5 million in 2022, then fell by 5.3% to -$4.7 million in 2023, then dropped by 15.13% to -$5.4 million in 2024, then crashed by 43.63% to -$7.8 million in 2025.
  • Business Quant data shows EBT for CLPT at -$7.8 million in Q4 2025, -$5.9 million in Q3 2025, and -$5.8 million in Q2 2025.